These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 26851801)

  • 1. BRAF Inhibitors and IFNα: Plus, Minus, or Indeterminate?
    Davar D; Fuchs SY; Kirkwood JM
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26851801
    [No Abstract]   [Full Text] [Related]  

  • 2. Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma.
    Sabbatino F; Wang Y; Scognamiglio G; Favoino E; Feldman SA; Villani V; Flaherty KT; Nota S; Giannarelli D; Simeone E; Anniciello AM; Palmieri G; Pepe S; Botti G; Ascierto PA; Ferrone CR; Ferrone S
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26851802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
    Suarez-Kelly LP; Kemper GM; Duggan MC; Stiff A; Noel TC; Markowitz J; Luedke EA; Yildiz VO; Yu L; Jaime-Ramirez AC; Karpa V; Zhang X; Carson WE
    Oncotarget; 2016 Dec; 7(49):81172-81186. PubMed ID: 27783987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urgent treatment of patients with metastatic melanoma using Braf inhibitors in the absence of Braf mutation status.
    Nathan P; Sharma A; Lorigan P
    Ann Oncol; 2013 Jun; 24(6):1712-3. PubMed ID: 23613475
    [No Abstract]   [Full Text] [Related]  

  • 5. Community experience of vemurafenib for BRAF(V600) melanoma.
    Hersey P
    Lancet Oncol; 2014 Apr; 15(4):369-70. PubMed ID: 24582506
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
    Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
    Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
    Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
    Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.
    Zhu G; Yi X; Haferkamp S; Hesbacher S; Li C; Goebeler M; Gao T; Houben R; Schrama D
    Cancer Lett; 2016 Jun; 376(1):43-52. PubMed ID: 27000992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.
    Zia Y; Chen L; Daud A
    Expert Opin Pharmacother; 2015; 16(14):2257-63. PubMed ID: 26331795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new standard of care for metastatic melanoma?
    Sharma SP
    Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559
    [No Abstract]   [Full Text] [Related]  

  • 11. Selumetinib increases the efficacy of first-line dacarbazine.
    Cancer Discov; 2013 Jul; 3(7):OF16. PubMed ID: 23847359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma.
    Queirolo P; Spagnolo F
    Cancer Metastasis Rev; 2017 Mar; 36(1):35-42. PubMed ID: 28299583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Has targeted therapy for melanoma made chemotherapy obsolete?
    Gibney GT; Sondak VK
    Lancet Oncol; 2013 Jul; 14(8):676-7. PubMed ID: 23816289
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
    Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
    Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
    Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged.
    Chapman PB; Solit DB; Rosen N
    Cancer Cell; 2014 Nov; 26(5):603-4. PubMed ID: 25517746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Confocal microscopy and dermoscopy for the monitoring of BRAF inhibitor therapy of melanoma skin metastases.
    Ribero S; Marra E; Tomasini CF; Fierro MT; Bombonato C; Longo C
    Br J Dermatol; 2017 Apr; 176(4):1101-1102. PubMed ID: 27515562
    [No Abstract]   [Full Text] [Related]  

  • 18. BRAF inhibitor activity in V600R metastatic melanoma--response.
    Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
    Eur J Cancer; 2013 May; 49(7):1797-8. PubMed ID: 23490649
    [No Abstract]   [Full Text] [Related]  

  • 19. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
    Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Response of BRAF(L597Q)-mutant melanoma to trametinib : Targeted melanoma therapy beyond BRAF(V600) mutations].
    Haase O; Angün O; Grätz V; Lüttmann N; Neumann A; Zillikens D; Terheyden P
    Hautarzt; 2016 Aug; 67(8):648-52. PubMed ID: 27146499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.